开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2224553, encodeId=b27622245539c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：2审修回去，现在是pending recommendation是啥意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f61b5715653, createdName=ms7000000615927982, createdTime=Sat Sep 07 11:32:46 CST 2024, time=2024-09-07, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2224040, encodeId=1e282224040e2, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3.20投稿，ADM: 为魏院士，6.22回来初审意见，8.31返修回去，第五天9.4变为 ADM: Lee, Cherish，Under Review，有这样变ADM的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Wed Sep 04 15:50:25 CST 2024, time=2024-09-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2145342, encodeId=5bd22145342cb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;综合期刊;综合医学 经验分享：2023年6月28日，Clarivate Analytics（科睿唯安）发布了2023年《期刊引证报告》（Journal Citation Reports / 简称JCR），创刊仅3年的MedComm获得了首个影响因子9.9！ MedComm编委团队由英国牛津大学罗莎琳德富兰克林研究所的James Henderson Naismith院士、耶鲁大学系统生物学研究所的Günter P. Wagner院士、四川大学华西医院的魏于全院士担任主编，汇集全球十多个国家的知名专家学者，组成优秀的国际化的编委团队。 2016年,主编魏于全院士创办了Signal Transduction and Targeted Therapy（STTT），期刊稳定发展，2023年实现高位增长，最新影响因子39.3。2020年8月，魏于全院士与荷兰格罗宁根大学Arnold J.M. Driessen院士（荷兰皇家科学院院士）还创办了Molecular Biomedicine期刊。仅2年，该刊也已被ESCI、PubMed和Scopus等权威数据库收录，并于2023年获得第一个影响因子4.0，潜力无限，未来可期。 此外，MedComm系列期刊还有3本姐妹刊于2022年正式创办：MedComm-Oncology、MedComm - Future Medicine和MedComm-Biomaterials and Applications，目前都已被DOAJ数据库收录。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:50:46 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2135567, encodeId=de6b213556e13, content=投稿之后undergoing initiate checking需要多久呀？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32a5499147, createdName=ms7000000232434905, createdTime=Tue May 16 19:04:47 CST 2023, time=2023-05-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2217316, encodeId=91d2221e3161e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：Submitted January 28, 2024 Final revisions submitted June 26, 2024 Accepted July 1, 2024 Version of Record online July 28, 2024 Article made open access July 28, 2024 上面为投稿时间线，整个时间周期还是比较长，但是编辑很专业，第一次给了大修，修得欲仙欲死，不过认真改完，最后还是很痛快的接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94d98363383, createdName=ms7000001456576784, createdTime=Mon Jul 29 07:59:38 CST 2024, time=2024-07-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222856, encodeId=5b75222285652, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿速度有点慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Wed Aug 28 17:10:40 CST 2024, time=2024-08-28, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2220171, encodeId=881622201e17b, content=Medcocomm目前是三区，2024-2025是否可能晋级中科院一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Aug 15 06:58:27 CST 2024, time=2024-08-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2221553, encodeId=14732221553a6, content=偏重的研究方向：肿瘤 经验分享：想问下大家under review了两个月变成pending decision了是什么情况，慌死了慌死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Tue Aug 20 16:49:45 CST 2024, time=2024-08-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2219982, encodeId=d1bb221998274, content=偏重的研究方向：基础研究 经验分享：ADM: Not Assigned Undergoing initial checking 这个状态十天了，还有可能送审吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/B47020B7D9BC417EFADBD15729C98AC1/100, createdBy=f89a2283632, createdName=科研凹凸曼, createdTime=Tue Aug 13 21:12:57 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省)]

2024-09-07 ms7000000615927982 来自陕西省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：综述
经验分享：2审修回去，现在是pending recommendation是啥意思？

7 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2224553, encodeId=b27622245539c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：2审修回去，现在是pending recommendation是啥意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f61b5715653, createdName=ms7000000615927982, createdTime=Sat Sep 07 11:32:46 CST 2024, time=2024-09-07, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2224040, encodeId=1e282224040e2, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3.20投稿，ADM: 为魏院士，6.22回来初审意见，8.31返修回去，第五天9.4变为 ADM: Lee, Cherish，Under Review，有这样变ADM的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Wed Sep 04 15:50:25 CST 2024, time=2024-09-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2145342, encodeId=5bd22145342cb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;综合期刊;综合医学 经验分享：2023年6月28日，Clarivate Analytics（科睿唯安）发布了2023年《期刊引证报告》（Journal Citation Reports / 简称JCR），创刊仅3年的MedComm获得了首个影响因子9.9！ MedComm编委团队由英国牛津大学罗莎琳德富兰克林研究所的James Henderson Naismith院士、耶鲁大学系统生物学研究所的Günter P. Wagner院士、四川大学华西医院的魏于全院士担任主编，汇集全球十多个国家的知名专家学者，组成优秀的国际化的编委团队。 2016年,主编魏于全院士创办了Signal Transduction and Targeted Therapy（STTT），期刊稳定发展，2023年实现高位增长，最新影响因子39.3。2020年8月，魏于全院士与荷兰格罗宁根大学Arnold J.M. Driessen院士（荷兰皇家科学院院士）还创办了Molecular Biomedicine期刊。仅2年，该刊也已被ESCI、PubMed和Scopus等权威数据库收录，并于2023年获得第一个影响因子4.0，潜力无限，未来可期。 此外，MedComm系列期刊还有3本姐妹刊于2022年正式创办：MedComm-Oncology、MedComm - Future Medicine和MedComm-Biomaterials and Applications，目前都已被DOAJ数据库收录。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:50:46 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2135567, encodeId=de6b213556e13, content=投稿之后undergoing initiate checking需要多久呀？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32a5499147, createdName=ms7000000232434905, createdTime=Tue May 16 19:04:47 CST 2023, time=2023-05-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2217316, encodeId=91d2221e3161e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：Submitted January 28, 2024 Final revisions submitted June 26, 2024 Accepted July 1, 2024 Version of Record online July 28, 2024 Article made open access July 28, 2024 上面为投稿时间线，整个时间周期还是比较长，但是编辑很专业，第一次给了大修，修得欲仙欲死，不过认真改完，最后还是很痛快的接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94d98363383, createdName=ms7000001456576784, createdTime=Mon Jul 29 07:59:38 CST 2024, time=2024-07-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222856, encodeId=5b75222285652, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿速度有点慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Wed Aug 28 17:10:40 CST 2024, time=2024-08-28, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2220171, encodeId=881622201e17b, content=Medcocomm目前是三区，2024-2025是否可能晋级中科院一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Aug 15 06:58:27 CST 2024, time=2024-08-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2221553, encodeId=14732221553a6, content=偏重的研究方向：肿瘤 经验分享：想问下大家under review了两个月变成pending decision了是什么情况，慌死了慌死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Tue Aug 20 16:49:45 CST 2024, time=2024-08-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2219982, encodeId=d1bb221998274, content=偏重的研究方向：基础研究 经验分享：ADM: Not Assigned Undergoing initial checking 这个状态十天了，还有可能送审吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/B47020B7D9BC417EFADBD15729C98AC1/100, createdBy=f89a2283632, createdName=科研凹凸曼, createdTime=Tue Aug 13 21:12:57 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省)]

2024-09-04 shuchao 来自湖南省

审稿速度:3.0 | 投稿命中率:25.0
经验分享：3.20投稿，ADM: 为魏院士，6.22回来初审意见，8.31返修回去，第五天9.4变为 ADM: Lee, Cherish，Under Review，有这样变ADM的嘛

11 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2224553, encodeId=b27622245539c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：2审修回去，现在是pending recommendation是啥意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f61b5715653, createdName=ms7000000615927982, createdTime=Sat Sep 07 11:32:46 CST 2024, time=2024-09-07, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2224040, encodeId=1e282224040e2, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3.20投稿，ADM: 为魏院士，6.22回来初审意见，8.31返修回去，第五天9.4变为 ADM: Lee, Cherish，Under Review，有这样变ADM的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Wed Sep 04 15:50:25 CST 2024, time=2024-09-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2145342, encodeId=5bd22145342cb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;综合期刊;综合医学 经验分享：2023年6月28日，Clarivate Analytics（科睿唯安）发布了2023年《期刊引证报告》（Journal Citation Reports / 简称JCR），创刊仅3年的MedComm获得了首个影响因子9.9！ MedComm编委团队由英国牛津大学罗莎琳德富兰克林研究所的James Henderson Naismith院士、耶鲁大学系统生物学研究所的Günter P. Wagner院士、四川大学华西医院的魏于全院士担任主编，汇集全球十多个国家的知名专家学者，组成优秀的国际化的编委团队。 2016年,主编魏于全院士创办了Signal Transduction and Targeted Therapy（STTT），期刊稳定发展，2023年实现高位增长，最新影响因子39.3。2020年8月，魏于全院士与荷兰格罗宁根大学Arnold J.M. Driessen院士（荷兰皇家科学院院士）还创办了Molecular Biomedicine期刊。仅2年，该刊也已被ESCI、PubMed和Scopus等权威数据库收录，并于2023年获得第一个影响因子4.0，潜力无限，未来可期。 此外，MedComm系列期刊还有3本姐妹刊于2022年正式创办：MedComm-Oncology、MedComm - Future Medicine和MedComm-Biomaterials and Applications，目前都已被DOAJ数据库收录。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:50:46 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2135567, encodeId=de6b213556e13, content=投稿之后undergoing initiate checking需要多久呀？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32a5499147, createdName=ms7000000232434905, createdTime=Tue May 16 19:04:47 CST 2023, time=2023-05-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2217316, encodeId=91d2221e3161e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：Submitted January 28, 2024 Final revisions submitted June 26, 2024 Accepted July 1, 2024 Version of Record online July 28, 2024 Article made open access July 28, 2024 上面为投稿时间线，整个时间周期还是比较长，但是编辑很专业，第一次给了大修，修得欲仙欲死，不过认真改完，最后还是很痛快的接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94d98363383, createdName=ms7000001456576784, createdTime=Mon Jul 29 07:59:38 CST 2024, time=2024-07-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222856, encodeId=5b75222285652, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿速度有点慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Wed Aug 28 17:10:40 CST 2024, time=2024-08-28, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2220171, encodeId=881622201e17b, content=Medcocomm目前是三区，2024-2025是否可能晋级中科院一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Aug 15 06:58:27 CST 2024, time=2024-08-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2221553, encodeId=14732221553a6, content=偏重的研究方向：肿瘤 经验分享：想问下大家under review了两个月变成pending decision了是什么情况，慌死了慌死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Tue Aug 20 16:49:45 CST 2024, time=2024-08-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2219982, encodeId=d1bb221998274, content=偏重的研究方向：基础研究 经验分享：ADM: Not Assigned Undergoing initial checking 这个状态十天了，还有可能送审吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/B47020B7D9BC417EFADBD15729C98AC1/100, createdBy=f89a2283632, createdName=科研凹凸曼, createdTime=Tue Aug 13 21:12:57 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省)]

2023-06-29 侠胆医心来自香港

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：转化医学;综合期刊;综合医学
经验分享：2023年6月28日，Clarivate Analytics（科睿唯安）发布了2023年《期刊引证报告》（Journal Citation Reports / 简称JCR），创刊仅3年的MedComm获得了首个影响因子9.9！

MedComm编委团队由英国牛津大学罗莎琳德富兰克林研究所的James Henderson Naismith院士、耶鲁大学系统生物学研究所的Günter P. Wagner院士、四川大学华西医院的魏于全院士担任主编，汇集全球十多个国家的知名专家学者，组成优秀的国际化的编委团队。
2016年,主编魏于全院士创办了Signal Transduction and Targeted Therapy（STTT），期刊稳定发展，2023年实现高位增长，最新影响因子39.3。2020年8月，魏于全院士与荷兰格罗宁根大学Arnold J.M. Driessen院士（荷兰皇家科学院院士）还创办了Molecular Biomedicine期刊。仅2年，该刊也已被ESCI、PubMed和Scopus等权威数据库收录，并于2023年获得第一个影响因子4.0，潜力无限，未来可期。

此外，MedComm系列期刊还有3本姐妹刊于2022年正式创办：MedComm-Oncology、MedComm - Future Medicine和MedComm-Biomaterials and Applications，目前都已被DOAJ数据库收录。

59 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2224553, encodeId=b27622245539c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：2审修回去，现在是pending recommendation是啥意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f61b5715653, createdName=ms7000000615927982, createdTime=Sat Sep 07 11:32:46 CST 2024, time=2024-09-07, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2224040, encodeId=1e282224040e2, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3.20投稿，ADM: 为魏院士，6.22回来初审意见，8.31返修回去，第五天9.4变为 ADM: Lee, Cherish，Under Review，有这样变ADM的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Wed Sep 04 15:50:25 CST 2024, time=2024-09-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2145342, encodeId=5bd22145342cb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;综合期刊;综合医学 经验分享：2023年6月28日，Clarivate Analytics（科睿唯安）发布了2023年《期刊引证报告》（Journal Citation Reports / 简称JCR），创刊仅3年的MedComm获得了首个影响因子9.9！ MedComm编委团队由英国牛津大学罗莎琳德富兰克林研究所的James Henderson Naismith院士、耶鲁大学系统生物学研究所的Günter P. Wagner院士、四川大学华西医院的魏于全院士担任主编，汇集全球十多个国家的知名专家学者，组成优秀的国际化的编委团队。 2016年,主编魏于全院士创办了Signal Transduction and Targeted Therapy（STTT），期刊稳定发展，2023年实现高位增长，最新影响因子39.3。2020年8月，魏于全院士与荷兰格罗宁根大学Arnold J.M. Driessen院士（荷兰皇家科学院院士）还创办了Molecular Biomedicine期刊。仅2年，该刊也已被ESCI、PubMed和Scopus等权威数据库收录，并于2023年获得第一个影响因子4.0，潜力无限，未来可期。 此外，MedComm系列期刊还有3本姐妹刊于2022年正式创办：MedComm-Oncology、MedComm - Future Medicine和MedComm-Biomaterials and Applications，目前都已被DOAJ数据库收录。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:50:46 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2135567, encodeId=de6b213556e13, content=投稿之后undergoing initiate checking需要多久呀？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32a5499147, createdName=ms7000000232434905, createdTime=Tue May 16 19:04:47 CST 2023, time=2023-05-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2217316, encodeId=91d2221e3161e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：Submitted January 28, 2024 Final revisions submitted June 26, 2024 Accepted July 1, 2024 Version of Record online July 28, 2024 Article made open access July 28, 2024 上面为投稿时间线，整个时间周期还是比较长，但是编辑很专业，第一次给了大修，修得欲仙欲死，不过认真改完，最后还是很痛快的接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94d98363383, createdName=ms7000001456576784, createdTime=Mon Jul 29 07:59:38 CST 2024, time=2024-07-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222856, encodeId=5b75222285652, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿速度有点慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Wed Aug 28 17:10:40 CST 2024, time=2024-08-28, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2220171, encodeId=881622201e17b, content=Medcocomm目前是三区，2024-2025是否可能晋级中科院一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Aug 15 06:58:27 CST 2024, time=2024-08-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2221553, encodeId=14732221553a6, content=偏重的研究方向：肿瘤 经验分享：想问下大家under review了两个月变成pending decision了是什么情况，慌死了慌死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Tue Aug 20 16:49:45 CST 2024, time=2024-08-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2219982, encodeId=d1bb221998274, content=偏重的研究方向：基础研究 经验分享：ADM: Not Assigned Undergoing initial checking 这个状态十天了，还有可能送审吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/B47020B7D9BC417EFADBD15729C98AC1/100, createdBy=f89a2283632, createdName=科研凹凸曼, createdTime=Tue Aug 13 21:12:57 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省)]

2024-05-27 shuchao 来自湖南省

审稿速度:3.0
经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？

78 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2224553, encodeId=b27622245539c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：2审修回去，现在是pending recommendation是啥意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f61b5715653, createdName=ms7000000615927982, createdTime=Sat Sep 07 11:32:46 CST 2024, time=2024-09-07, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2224040, encodeId=1e282224040e2, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3.20投稿，ADM: 为魏院士，6.22回来初审意见，8.31返修回去，第五天9.4变为 ADM: Lee, Cherish，Under Review，有这样变ADM的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Wed Sep 04 15:50:25 CST 2024, time=2024-09-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2145342, encodeId=5bd22145342cb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;综合期刊;综合医学 经验分享：2023年6月28日，Clarivate Analytics（科睿唯安）发布了2023年《期刊引证报告》（Journal Citation Reports / 简称JCR），创刊仅3年的MedComm获得了首个影响因子9.9！ MedComm编委团队由英国牛津大学罗莎琳德富兰克林研究所的James Henderson Naismith院士、耶鲁大学系统生物学研究所的Günter P. Wagner院士、四川大学华西医院的魏于全院士担任主编，汇集全球十多个国家的知名专家学者，组成优秀的国际化的编委团队。 2016年,主编魏于全院士创办了Signal Transduction and Targeted Therapy（STTT），期刊稳定发展，2023年实现高位增长，最新影响因子39.3。2020年8月，魏于全院士与荷兰格罗宁根大学Arnold J.M. Driessen院士（荷兰皇家科学院院士）还创办了Molecular Biomedicine期刊。仅2年，该刊也已被ESCI、PubMed和Scopus等权威数据库收录，并于2023年获得第一个影响因子4.0，潜力无限，未来可期。 此外，MedComm系列期刊还有3本姐妹刊于2022年正式创办：MedComm-Oncology、MedComm - Future Medicine和MedComm-Biomaterials and Applications，目前都已被DOAJ数据库收录。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:50:46 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2135567, encodeId=de6b213556e13, content=投稿之后undergoing initiate checking需要多久呀？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32a5499147, createdName=ms7000000232434905, createdTime=Tue May 16 19:04:47 CST 2023, time=2023-05-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2217316, encodeId=91d2221e3161e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：Submitted January 28, 2024 Final revisions submitted June 26, 2024 Accepted July 1, 2024 Version of Record online July 28, 2024 Article made open access July 28, 2024 上面为投稿时间线，整个时间周期还是比较长，但是编辑很专业，第一次给了大修，修得欲仙欲死，不过认真改完，最后还是很痛快的接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94d98363383, createdName=ms7000001456576784, createdTime=Mon Jul 29 07:59:38 CST 2024, time=2024-07-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222856, encodeId=5b75222285652, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿速度有点慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Wed Aug 28 17:10:40 CST 2024, time=2024-08-28, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2220171, encodeId=881622201e17b, content=Medcocomm目前是三区，2024-2025是否可能晋级中科院一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Aug 15 06:58:27 CST 2024, time=2024-08-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2221553, encodeId=14732221553a6, content=偏重的研究方向：肿瘤 经验分享：想问下大家under review了两个月变成pending decision了是什么情况，慌死了慌死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Tue Aug 20 16:49:45 CST 2024, time=2024-08-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2219982, encodeId=d1bb221998274, content=偏重的研究方向：基础研究 经验分享：ADM: Not Assigned Undergoing initial checking 这个状态十天了，还有可能送审吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/B47020B7D9BC417EFADBD15729C98AC1/100, createdBy=f89a2283632, createdName=科研凹凸曼, createdTime=Tue Aug 13 21:12:57 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省)]

2023-05-16 ms7000000232434905 来自北京

投稿之后undergoing initiate checking需要多久呀？

66 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2224553, encodeId=b27622245539c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：2审修回去，现在是pending recommendation是啥意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f61b5715653, createdName=ms7000000615927982, createdTime=Sat Sep 07 11:32:46 CST 2024, time=2024-09-07, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2224040, encodeId=1e282224040e2, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3.20投稿，ADM: 为魏院士，6.22回来初审意见，8.31返修回去，第五天9.4变为 ADM: Lee, Cherish，Under Review，有这样变ADM的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Wed Sep 04 15:50:25 CST 2024, time=2024-09-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2145342, encodeId=5bd22145342cb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;综合期刊;综合医学 经验分享：2023年6月28日，Clarivate Analytics（科睿唯安）发布了2023年《期刊引证报告》（Journal Citation Reports / 简称JCR），创刊仅3年的MedComm获得了首个影响因子9.9！ MedComm编委团队由英国牛津大学罗莎琳德富兰克林研究所的James Henderson Naismith院士、耶鲁大学系统生物学研究所的Günter P. Wagner院士、四川大学华西医院的魏于全院士担任主编，汇集全球十多个国家的知名专家学者，组成优秀的国际化的编委团队。 2016年,主编魏于全院士创办了Signal Transduction and Targeted Therapy（STTT），期刊稳定发展，2023年实现高位增长，最新影响因子39.3。2020年8月，魏于全院士与荷兰格罗宁根大学Arnold J.M. Driessen院士（荷兰皇家科学院院士）还创办了Molecular Biomedicine期刊。仅2年，该刊也已被ESCI、PubMed和Scopus等权威数据库收录，并于2023年获得第一个影响因子4.0，潜力无限，未来可期。 此外，MedComm系列期刊还有3本姐妹刊于2022年正式创办：MedComm-Oncology、MedComm - Future Medicine和MedComm-Biomaterials and Applications，目前都已被DOAJ数据库收录。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:50:46 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2135567, encodeId=de6b213556e13, content=投稿之后undergoing initiate checking需要多久呀？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32a5499147, createdName=ms7000000232434905, createdTime=Tue May 16 19:04:47 CST 2023, time=2023-05-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2217316, encodeId=91d2221e3161e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：Submitted January 28, 2024 Final revisions submitted June 26, 2024 Accepted July 1, 2024 Version of Record online July 28, 2024 Article made open access July 28, 2024 上面为投稿时间线，整个时间周期还是比较长，但是编辑很专业，第一次给了大修，修得欲仙欲死，不过认真改完，最后还是很痛快的接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94d98363383, createdName=ms7000001456576784, createdTime=Mon Jul 29 07:59:38 CST 2024, time=2024-07-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222856, encodeId=5b75222285652, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿速度有点慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Wed Aug 28 17:10:40 CST 2024, time=2024-08-28, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2220171, encodeId=881622201e17b, content=Medcocomm目前是三区，2024-2025是否可能晋级中科院一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Aug 15 06:58:27 CST 2024, time=2024-08-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2221553, encodeId=14732221553a6, content=偏重的研究方向：肿瘤 经验分享：想问下大家under review了两个月变成pending decision了是什么情况，慌死了慌死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Tue Aug 20 16:49:45 CST 2024, time=2024-08-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2219982, encodeId=d1bb221998274, content=偏重的研究方向：基础研究 经验分享：ADM: Not Assigned Undergoing initial checking 这个状态十天了，还有可能送审吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/B47020B7D9BC417EFADBD15729C98AC1/100, createdBy=f89a2283632, createdName=科研凹凸曼, createdTime=Tue Aug 13 21:12:57 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省)]

2024-07-29 ms7000001456576784 来自湖北省

审稿速度:2.0 | 投稿命中率:75.0
经验分享：Submitted
January 28, 2024
Final revisions submitted
June 26, 2024
Accepted
July 1, 2024
Version of Record online
July 28, 2024
Article made open access
July 28, 2024

上面为投稿时间线，整个时间周期还是比较长，但是编辑很专业，第一次给了大修，修得欲仙欲死，不过认真改完，最后还是很痛快的接收了。

51 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2224553, encodeId=b27622245539c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：2审修回去，现在是pending recommendation是啥意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f61b5715653, createdName=ms7000000615927982, createdTime=Sat Sep 07 11:32:46 CST 2024, time=2024-09-07, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2224040, encodeId=1e282224040e2, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3.20投稿，ADM: 为魏院士，6.22回来初审意见，8.31返修回去，第五天9.4变为 ADM: Lee, Cherish，Under Review，有这样变ADM的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Wed Sep 04 15:50:25 CST 2024, time=2024-09-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2145342, encodeId=5bd22145342cb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;综合期刊;综合医学 经验分享：2023年6月28日，Clarivate Analytics（科睿唯安）发布了2023年《期刊引证报告》（Journal Citation Reports / 简称JCR），创刊仅3年的MedComm获得了首个影响因子9.9！ MedComm编委团队由英国牛津大学罗莎琳德富兰克林研究所的James Henderson Naismith院士、耶鲁大学系统生物学研究所的Günter P. Wagner院士、四川大学华西医院的魏于全院士担任主编，汇集全球十多个国家的知名专家学者，组成优秀的国际化的编委团队。 2016年,主编魏于全院士创办了Signal Transduction and Targeted Therapy（STTT），期刊稳定发展，2023年实现高位增长，最新影响因子39.3。2020年8月，魏于全院士与荷兰格罗宁根大学Arnold J.M. Driessen院士（荷兰皇家科学院院士）还创办了Molecular Biomedicine期刊。仅2年，该刊也已被ESCI、PubMed和Scopus等权威数据库收录，并于2023年获得第一个影响因子4.0，潜力无限，未来可期。 此外，MedComm系列期刊还有3本姐妹刊于2022年正式创办：MedComm-Oncology、MedComm - Future Medicine和MedComm-Biomaterials and Applications，目前都已被DOAJ数据库收录。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:50:46 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2135567, encodeId=de6b213556e13, content=投稿之后undergoing initiate checking需要多久呀？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32a5499147, createdName=ms7000000232434905, createdTime=Tue May 16 19:04:47 CST 2023, time=2023-05-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2217316, encodeId=91d2221e3161e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：Submitted January 28, 2024 Final revisions submitted June 26, 2024 Accepted July 1, 2024 Version of Record online July 28, 2024 Article made open access July 28, 2024 上面为投稿时间线，整个时间周期还是比较长，但是编辑很专业，第一次给了大修，修得欲仙欲死，不过认真改完，最后还是很痛快的接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94d98363383, createdName=ms7000001456576784, createdTime=Mon Jul 29 07:59:38 CST 2024, time=2024-07-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222856, encodeId=5b75222285652, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿速度有点慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Wed Aug 28 17:10:40 CST 2024, time=2024-08-28, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2220171, encodeId=881622201e17b, content=Medcocomm目前是三区，2024-2025是否可能晋级中科院一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Aug 15 06:58:27 CST 2024, time=2024-08-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2221553, encodeId=14732221553a6, content=偏重的研究方向：肿瘤 经验分享：想问下大家under review了两个月变成pending decision了是什么情况，慌死了慌死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Tue Aug 20 16:49:45 CST 2024, time=2024-08-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2219982, encodeId=d1bb221998274, content=偏重的研究方向：基础研究 经验分享：ADM: Not Assigned Undergoing initial checking 这个状态十天了，还有可能送审吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/B47020B7D9BC417EFADBD15729C98AC1/100, createdBy=f89a2283632, createdName=科研凹凸曼, createdTime=Tue Aug 13 21:12:57 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省)]

2024-08-28 snowboy 来自云南省

审稿速度:3.0 | 投稿命中率:50.0
经验分享：审稿速度有点慢

23 0

[GetPortalCommentsPageByObjectIdResponse(id=2224553, encodeId=b27622245539c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：2审修回去，现在是pending recommendation是啥意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f61b5715653, createdName=ms7000000615927982, createdTime=Sat Sep 07 11:32:46 CST 2024, time=2024-09-07, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2224040, encodeId=1e282224040e2, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3.20投稿，ADM: 为魏院士，6.22回来初审意见，8.31返修回去，第五天9.4变为 ADM: Lee, Cherish，Under Review，有这样变ADM的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Wed Sep 04 15:50:25 CST 2024, time=2024-09-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2145342, encodeId=5bd22145342cb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;综合期刊;综合医学 经验分享：2023年6月28日，Clarivate Analytics（科睿唯安）发布了2023年《期刊引证报告》（Journal Citation Reports / 简称JCR），创刊仅3年的MedComm获得了首个影响因子9.9！ MedComm编委团队由英国牛津大学罗莎琳德富兰克林研究所的James Henderson Naismith院士、耶鲁大学系统生物学研究所的Günter P. Wagner院士、四川大学华西医院的魏于全院士担任主编，汇集全球十多个国家的知名专家学者，组成优秀的国际化的编委团队。 2016年,主编魏于全院士创办了Signal Transduction and Targeted Therapy（STTT），期刊稳定发展，2023年实现高位增长，最新影响因子39.3。2020年8月，魏于全院士与荷兰格罗宁根大学Arnold J.M. Driessen院士（荷兰皇家科学院院士）还创办了Molecular Biomedicine期刊。仅2年，该刊也已被ESCI、PubMed和Scopus等权威数据库收录，并于2023年获得第一个影响因子4.0，潜力无限，未来可期。 此外，MedComm系列期刊还有3本姐妹刊于2022年正式创办：MedComm-Oncology、MedComm - Future Medicine和MedComm-Biomaterials and Applications，目前都已被DOAJ数据库收录。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:50:46 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2135567, encodeId=de6b213556e13, content=投稿之后undergoing initiate checking需要多久呀？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32a5499147, createdName=ms7000000232434905, createdTime=Tue May 16 19:04:47 CST 2023, time=2023-05-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2217316, encodeId=91d2221e3161e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：Submitted January 28, 2024 Final revisions submitted June 26, 2024 Accepted July 1, 2024 Version of Record online July 28, 2024 Article made open access July 28, 2024 上面为投稿时间线，整个时间周期还是比较长，但是编辑很专业，第一次给了大修，修得欲仙欲死，不过认真改完，最后还是很痛快的接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94d98363383, createdName=ms7000001456576784, createdTime=Mon Jul 29 07:59:38 CST 2024, time=2024-07-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222856, encodeId=5b75222285652, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿速度有点慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Wed Aug 28 17:10:40 CST 2024, time=2024-08-28, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2220171, encodeId=881622201e17b, content=Medcocomm目前是三区，2024-2025是否可能晋级中科院一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Aug 15 06:58:27 CST 2024, time=2024-08-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2221553, encodeId=14732221553a6, content=偏重的研究方向：肿瘤 经验分享：想问下大家under review了两个月变成pending decision了是什么情况，慌死了慌死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Tue Aug 20 16:49:45 CST 2024, time=2024-08-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2219982, encodeId=d1bb221998274, content=偏重的研究方向：基础研究 经验分享：ADM: Not Assigned Undergoing initial checking 这个状态十天了，还有可能送审吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/B47020B7D9BC417EFADBD15729C98AC1/100, createdBy=f89a2283632, createdName=科研凹凸曼, createdTime=Tue Aug 13 21:12:57 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省)]

2024-08-15 ms1000000907051820 来自河南省

Medcocomm目前是三区，2024-2025是否可能晋级中科院一区嘛？

142 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2224553, encodeId=b27622245539c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：2审修回去，现在是pending recommendation是啥意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f61b5715653, createdName=ms7000000615927982, createdTime=Sat Sep 07 11:32:46 CST 2024, time=2024-09-07, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2224040, encodeId=1e282224040e2, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3.20投稿，ADM: 为魏院士，6.22回来初审意见，8.31返修回去，第五天9.4变为 ADM: Lee, Cherish，Under Review，有这样变ADM的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Wed Sep 04 15:50:25 CST 2024, time=2024-09-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2145342, encodeId=5bd22145342cb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;综合期刊;综合医学 经验分享：2023年6月28日，Clarivate Analytics（科睿唯安）发布了2023年《期刊引证报告》（Journal Citation Reports / 简称JCR），创刊仅3年的MedComm获得了首个影响因子9.9！ MedComm编委团队由英国牛津大学罗莎琳德富兰克林研究所的James Henderson Naismith院士、耶鲁大学系统生物学研究所的Günter P. Wagner院士、四川大学华西医院的魏于全院士担任主编，汇集全球十多个国家的知名专家学者，组成优秀的国际化的编委团队。 2016年,主编魏于全院士创办了Signal Transduction and Targeted Therapy（STTT），期刊稳定发展，2023年实现高位增长，最新影响因子39.3。2020年8月，魏于全院士与荷兰格罗宁根大学Arnold J.M. Driessen院士（荷兰皇家科学院院士）还创办了Molecular Biomedicine期刊。仅2年，该刊也已被ESCI、PubMed和Scopus等权威数据库收录，并于2023年获得第一个影响因子4.0，潜力无限，未来可期。 此外，MedComm系列期刊还有3本姐妹刊于2022年正式创办：MedComm-Oncology、MedComm - Future Medicine和MedComm-Biomaterials and Applications，目前都已被DOAJ数据库收录。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:50:46 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2135567, encodeId=de6b213556e13, content=投稿之后undergoing initiate checking需要多久呀？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32a5499147, createdName=ms7000000232434905, createdTime=Tue May 16 19:04:47 CST 2023, time=2023-05-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2217316, encodeId=91d2221e3161e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：Submitted January 28, 2024 Final revisions submitted June 26, 2024 Accepted July 1, 2024 Version of Record online July 28, 2024 Article made open access July 28, 2024 上面为投稿时间线，整个时间周期还是比较长，但是编辑很专业，第一次给了大修，修得欲仙欲死，不过认真改完，最后还是很痛快的接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94d98363383, createdName=ms7000001456576784, createdTime=Mon Jul 29 07:59:38 CST 2024, time=2024-07-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222856, encodeId=5b75222285652, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿速度有点慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Wed Aug 28 17:10:40 CST 2024, time=2024-08-28, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2220171, encodeId=881622201e17b, content=Medcocomm目前是三区，2024-2025是否可能晋级中科院一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Aug 15 06:58:27 CST 2024, time=2024-08-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2221553, encodeId=14732221553a6, content=偏重的研究方向：肿瘤 经验分享：想问下大家under review了两个月变成pending decision了是什么情况，慌死了慌死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Tue Aug 20 16:49:45 CST 2024, time=2024-08-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2219982, encodeId=d1bb221998274, content=偏重的研究方向：基础研究 经验分享：ADM: Not Assigned Undergoing initial checking 这个状态十天了，还有可能送审吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/B47020B7D9BC417EFADBD15729C98AC1/100, createdBy=f89a2283632, createdName=科研凹凸曼, createdTime=Tue Aug 13 21:12:57 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省)]

2024-08-20 ms4000000529451557 来自河南省

偏重的研究方向：肿瘤
经验分享：想问下大家under review了两个月变成pending decision了是什么情况，慌死了慌死了。

36 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2224553, encodeId=b27622245539c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：2审修回去，现在是pending recommendation是啥意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f61b5715653, createdName=ms7000000615927982, createdTime=Sat Sep 07 11:32:46 CST 2024, time=2024-09-07, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2224040, encodeId=1e282224040e2, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：3.20投稿，ADM: 为魏院士，6.22回来初审意见，8.31返修回去，第五天9.4变为 ADM: Lee, Cherish，Under Review，有这样变ADM的嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Wed Sep 04 15:50:25 CST 2024, time=2024-09-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2145342, encodeId=5bd22145342cb, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;综合期刊;综合医学 经验分享：2023年6月28日，Clarivate Analytics（科睿唯安）发布了2023年《期刊引证报告》（Journal Citation Reports / 简称JCR），创刊仅3年的MedComm获得了首个影响因子9.9！ MedComm编委团队由英国牛津大学罗莎琳德富兰克林研究所的James Henderson Naismith院士、耶鲁大学系统生物学研究所的Günter P. Wagner院士、四川大学华西医院的魏于全院士担任主编，汇集全球十多个国家的知名专家学者，组成优秀的国际化的编委团队。 2016年,主编魏于全院士创办了Signal Transduction and Targeted Therapy（STTT），期刊稳定发展，2023年实现高位增长，最新影响因子39.3。2020年8月，魏于全院士与荷兰格罗宁根大学Arnold J.M. Driessen院士（荷兰皇家科学院院士）还创办了Molecular Biomedicine期刊。仅2年，该刊也已被ESCI、PubMed和Scopus等权威数据库收录，并于2023年获得第一个影响因子4.0，潜力无限，未来可期。 此外，MedComm系列期刊还有3本姐妹刊于2022年正式创办：MedComm-Oncology、MedComm - Future Medicine和MedComm-Biomaterials and Applications，目前都已被DOAJ数据库收录。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:50:46 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2206853, encodeId=d8432206853aa, content=审稿速度:3.0 经验分享：审稿两个多月，从under review变为Pending Recommendation，这过程会维持多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=shuchao, createdTime=Mon May 27 14:49:42 CST 2024, time=2024-05-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2135567, encodeId=de6b213556e13, content=投稿之后undergoing initiate checking需要多久呀？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32a5499147, createdName=ms7000000232434905, createdTime=Tue May 16 19:04:47 CST 2023, time=2023-05-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2217316, encodeId=91d2221e3161e, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：Submitted January 28, 2024 Final revisions submitted June 26, 2024 Accepted July 1, 2024 Version of Record online July 28, 2024 Article made open access July 28, 2024 上面为投稿时间线，整个时间周期还是比较长，但是编辑很专业，第一次给了大修，修得欲仙欲死，不过认真改完，最后还是很痛快的接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94d98363383, createdName=ms7000001456576784, createdTime=Mon Jul 29 07:59:38 CST 2024, time=2024-07-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2222856, encodeId=5b75222285652, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿速度有点慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0b8e10256, createdName=snowboy, createdTime=Wed Aug 28 17:10:40 CST 2024, time=2024-08-28, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2220171, encodeId=881622201e17b, content=Medcocomm目前是三区，2024-2025是否可能晋级中科院一区嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Aug 15 06:58:27 CST 2024, time=2024-08-15, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2221553, encodeId=14732221553a6, content=偏重的研究方向：肿瘤 经验分享：想问下大家under review了两个月变成pending decision了是什么情况，慌死了慌死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Tue Aug 20 16:49:45 CST 2024, time=2024-08-20, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2219982, encodeId=d1bb221998274, content=偏重的研究方向：基础研究 经验分享：ADM: Not Assigned Undergoing initial checking 这个状态十天了，还有可能送审吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/B47020B7D9BC417EFADBD15729C98AC1/100, createdBy=f89a2283632, createdName=科研凹凸曼, createdTime=Tue Aug 13 21:12:57 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省)]

2024-08-13 科研凹凸曼来自湖北省

偏重的研究方向：基础研究
经验分享：ADM: Not Assigned

Undergoing initial checking
这个状态十天了，还有可能送审吗？

44 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务